PBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Pressure BioSciences's Revenue for the three months ended in Sep. 2023 was $0.41 Mil. Pressure BioSciences's Total Assets for the quarter that ended in Sep. 2023 was $1.64 Mil. Therefore, Pressure BioSciences's Asset Turnover for the quarter that ended in Sep. 2023 was 0.25.
Asset Turnover is linked to ROE % through Du Pont Formula. Pressure BioSciences's annualized ROE % for the quarter that ended in Sep. 2023 was 83.85%. It is also linked to ROA % through Du Pont Formula. Pressure BioSciences's annualized ROA % for the quarter that ended in Sep. 2023 was -1,374.01%.
The historical data trend for Pressure BioSciences's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pressure BioSciences Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Asset Turnover | Get a 7-Day Free Trial | 1.08 | 0.86 | 0.59 | 0.78 | 0.71 |
Pressure BioSciences Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Asset Turnover | Get a 7-Day Free Trial | 0.05 | 0.25 | 0.35 | 0.26 | 0.25 |
For the Medical Devices subindustry, Pressure BioSciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Pressure BioSciences's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Pressure BioSciences's Asset Turnover falls into.
Asset Turnover measures how quickly a company turns over its asset through sales.
Pressure BioSciences's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2022 ) | / | ( (Total Assets (A: Dec. 2021 ) | + | Total Assets (A: Dec. 2022 )) | / count ) |
= | 1.729 | / | ( (2.832 | + | 2.01) | / 2 ) |
= | 1.729 | / | 2.421 | |||
= | 0.71 |
Pressure BioSciences's Asset Turnover for the quarter that ended in Sep. 2023 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Sep. 2023 ) | / | ( (Total Assets (Q: Jun. 2023 ) | + | Total Assets (Q: Sep. 2023 )) | / count ) |
= | 0.413 | / | ( (1.676 | + | 1.602) | / 2 ) |
= | 0.413 | / | 1.639 | |||
= | 0.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Pressure BioSciences (OTCPK:PBIO) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Pressure BioSciences's annulized ROE % for the quarter that ended in Sep. 2023 is
ROE %** | (Q: Sep. 2023 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | -22.52 | / | -26.858 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-22.52 / 1.652) | * | (1.652 / 1.639) | * | (1.639/ -26.858) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | -1363.2 % | * | 1.0079 | * | -0.061 |
= | ROA % | * | Equity Multiplier | ||
= | -1,374.01 % | * | -0.061 | ||
= | 83.85 % |
Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Pressure BioSciences's annulized ROA % for the quarter that ended in Sep. 2023 is
ROA % | (Q: Sep. 2023 ) | ||
= | Net Income | / | Total Assets |
= | -22.52 | / | 1.639 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (-22.52 / 1.652) | * | (1.652 / 1.639) |
= | Net Margin % | * | Asset Turnover |
= | -1363.2 % | * | 1.0079 |
= | -1,374.01 % |
Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of Pressure BioSciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Joseph Shea | officer: Senior Vice President & CFO | 2 MINUTEMAN ROAD, MEDFIELD MA 02052 |
Bradford Addison Young | officer: Chief Commercial Officer | 513 LITTLE JOHN HILL, ANNAPOLIS MD 21405 |
Richard T Schumacher | director, officer: Chief Executive Officer | 375 WEST STREET, WEST BRIDGEWATER MA 02379 |
Nathan Lawrence | other: VP Sales and Marketing | 321 MANLEY STREET, WEST BRIDGEWATER MA 02379 |
Richard Thomley | officer: Chief Financial Officer | C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375 |
Kevin Pollack | director | 150 RAINVILLE ROAD, TARPON SPRINGS FL 34689 |
Michael S Urdea | director | 100 BUNCE MEADOWS DRIVE, ALAMO CA 94507 |
Alexander V Lazarev | officer: VP of REsearch and Development | 18 WINCHESTER DRIVE, LEXINGTON MA 02420 |
Edmund Y Ting | officer: Senior VP of Engineering | 23642 123RD PLACE SOUTHEAST, KENT WA 48031 |
Vito J Mangiardi | director | 12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903 |
Jeffrey N Peterson | director | 1031 SHORELINE DRIVE, SAN MATEO CA 94404 |
Mir Conrad F | officer: CFO | 19 BRIER LANE, CLIFTON NJ 07012 |
Clayton A Struve | 10 percent owner | 175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604 |
Css Llc/il | other: (a) | 175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604 |
R Wayne Fritzsche | director | 835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067 |
From GuruFocus
By sperokesalga sperokesalga • 06-01-2023
By ACCESSWIRE • 06-27-2023
By ACCESSWIRE • 06-27-2023
By ACCESSWIRE • 11-20-2023
By ACCESSWIRE • 08-22-2023
By ACCESSWIRE ACCESSWIRE • 05-10-2023
By ACCESSWIRE • 09-08-2023
By ACCESSWIRE • 10-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.